Skip to content
Menu

Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Lowers Price Target to $160

Benzinga Newsdesk 2 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and lowers the price target from $166 to $160.

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and lowers the price target from $166 to $160.

Read at benzinga.com